May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

Keytruda fails in previously treated TNBC
Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in

Read the full 331 word article

How to gain access

Continue reading with a
two-week free trial.